Loncar Cancer Immunotherapy ETF (CNCR) Sharpe Ratio

Sharpe ratio is not yet available for CNCR. This metric requires at least 12 months of historical daily returns to calculate. Check back once this data is available.

How it compares to other similar ETFs

The table compares Loncar Cancer Immunotherapy ETF's Sharpe Ratio with other ETFs in the Health & Biotech Equities category across multiple time periods, showing how CNCR's risk-adjusted performance compares to similar funds.

Data shows 1-, 5-, and 10-year periods, plus each fund's all-time average, as of Jun 3, 2026.

Symbol	Name	1Y Sharpe Ratio
BBC	Virtus LifeSci Biotech Clinical Trials ETF	3.49
LFSC	F/m Emerald Life Sciences Innovation ETF	2.33
SBIO	ALPS Medical Breakthroughs ETF	2.30
XBI	SPDR S&P Biotech ETF	2.28
IHE	iShares U.S. Pharmaceuticals ETF	2.28
CANC	Tema Oncology ETF	2.14
IBRN	iShares Neuroscience and Healthcare ETF	2.09
PJP	Invesco Dynamic Pharmaceuticals ETF	2.05
GNOM	Global X Genomics & Biotechnology ETF	2.04
FTXH	First Trust Nasdaq Pharmaceuticals ETF	2.04
CNCR	Loncar Cancer Immunotherapy ETF	—

Benchmark Against

Benchmark

S&P 500 Index

Lookback Period

How to choose period

Historical Sharpe Ratio

The chart shows CNCR's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when CNCR consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does CNCR fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio